Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabrizio Vernieri

Showing results (141-150 of 188) with videos related to

Pageof 19
Sort By:
Experimental Neurology|February 13, 2007
fMRI-vs-MEG evaluation of post-stroke interhemispheric asymmetries in primary sensorimotor hand areasClaudia Altamura, Kahtya Torquati, Filippo Zappasodi, et al.
The Journal of Headache and Pain|April 10, 2022
Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.
Journal of Neurology|June 25, 2021
Shorter visual aura characterizes young and middle-aged stroke patients with migraine with auraClaudia Altamura, Angelo Cascio Rizzo, Giovanna Viticchi, et al.
Headache|December 18, 2020
Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life studyPiero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
Headache|July 26, 2021
Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 studyPiero Barbanti, Cinzia Aurilia, Sabina Cevoli, et al.
Parkinsonism & Related Disorders|April 13, 2015
Movement disorders and brain iron overload in a new subtype of aceruloplasminemiaJean-Marc Melgari, Massimo Marano, Carlo Cosimo Quattrocchi, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|October 16, 2025
The second interim analysis of Italian participants enrolled in the real-world, Pan-European, prospective, observational, Phase 4 PEARL study of fremanezumab effectivenessFabrizio Vernieri, Anna Ambrosini, Marco Bartolini, et al.
Headache|June 14, 2021
Clinical features, disease progression, and use of healthcare resources in a large sample of 866 patients from 24 headache centers: A real-life perspective from the Italian chROnic migraiNe (IRON) projectPiero Barbanti, Luisa Fofi, Licia Grazzi, et al.
Journal of Clinical Neurology (Seoul, Korea)|April 14, 2016
Regional MRI Diffusion, White-Matter Hyperintensities, and Cognitive Function in Alzheimer's Disease and Vascular DementiaClaudia Altamura, Federica Scrascia, Carlo Cosimo Quattrocchi, et al.
The Journal of Headache and Pain|December 19, 2021
Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort studyFabrizio Vernieri, Nicoletta Brunelli, Roberta Messina, et al.
Pageof 19

Showing results (141-150 of 188) with videos related to

Sort By:
Pageof 19
Experimental Neurology|February 13, 2007
fMRI-vs-MEG evaluation of post-stroke interhemispheric asymmetries in primary sensorimotor hand areasClaudia Altamura, Kahtya Torquati, Filippo Zappasodi, et al.
The Journal of Headache and Pain|April 10, 2022
Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.
Journal of Neurology|June 25, 2021
Shorter visual aura characterizes young and middle-aged stroke patients with migraine with auraClaudia Altamura, Angelo Cascio Rizzo, Giovanna Viticchi, et al.
Headache|December 18, 2020
Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life studyPiero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
Headache|July 26, 2021
Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 studyPiero Barbanti, Cinzia Aurilia, Sabina Cevoli, et al.
Parkinsonism & Related Disorders|April 13, 2015
Movement disorders and brain iron overload in a new subtype of aceruloplasminemiaJean-Marc Melgari, Massimo Marano, Carlo Cosimo Quattrocchi, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|October 16, 2025
The second interim analysis of Italian participants enrolled in the real-world, Pan-European, prospective, observational, Phase 4 PEARL study of fremanezumab effectivenessFabrizio Vernieri, Anna Ambrosini, Marco Bartolini, et al.
Headache|June 14, 2021
Clinical features, disease progression, and use of healthcare resources in a large sample of 866 patients from 24 headache centers: A real-life perspective from the Italian chROnic migraiNe (IRON) projectPiero Barbanti, Luisa Fofi, Licia Grazzi, et al.
Journal of Clinical Neurology (Seoul, Korea)|April 14, 2016
Regional MRI Diffusion, White-Matter Hyperintensities, and Cognitive Function in Alzheimer's Disease and Vascular DementiaClaudia Altamura, Federica Scrascia, Carlo Cosimo Quattrocchi, et al.
The Journal of Headache and Pain|December 19, 2021
Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort studyFabrizio Vernieri, Nicoletta Brunelli, Roberta Messina, et al.
Pageof 19